<DOC>
	<DOC>NCT00327223</DOC>
	<brief_summary>AMP-011 is a Phase 1 study designed to extend the understanding of the toxicity and pharmacology of imexon by investigating a schedule of daily treatment for 5 days every three weeks. The objective of the study is to determine the maximally tolerated dose, the pharmacokinetics, and the toxicity of the drug on the designated schedule.</brief_summary>
	<brief_title>Safety Study of Imexon Treatment of Patients With Metastatic or Disseminated Malignancy</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<criteria>Previously treated malignant disease of any type. Prior treatment; at least one prior regimen required. Able to perform the activities of daily living. Off prior cancer therapy for at least 4 weeks. If female, neither pregnant nor nursing. Willing to use contraceptives to prevent pregnancy. No other serious illnesses. No other active malignancy. No serious infections. No other current drug therapy for the cancer. Blood counts and blood chemistries in or near normal range. Prior radiation is permitted. No active brain metastases.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>Metastatic cancer</keyword>
	<keyword>Disseminated malignant disease</keyword>
</DOC>